BI 685509 + propranolol

BI 685509 + PRD9566374 is an investigational combination therapy being developed by Boehringer Ingelheim for the treatment of clinically significant portal hypertension (CSPH) in patients with liver cirrhosis. BI 685509 is a soluble guanylate cyclase (sGC) stimulator that increases cyclic guanosine monophosphate (cGMP) levels, promoting vasodilation in the hepatic vasculature and reducing intrahepatic resistance. PRD9566374 is the internal code name for propranolol, a non-selective beta-adrenergic receptor blocker that reduces portal pressure by decreasing portal venous inflow through reduced cardiac output and splanchnic vasoconstriction. The combination aims to provide a synergistic reduction in portal pressure by targeting both intrahepatic resistance and splanchnic blood flow, potentially offering a more effective treatment option for patients with advanced liver disease and its complications.

Other names

BI 685509 + propranolol hydrochloride